Download App

Log in to access Online Inquiry
Company Overview More
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
CEO: Leonard M.D., John M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

NTLA Intellia Therapeutics

46.940-1.390-2.88%
Close 05/18 20:00 ET
46.94000.00%
Post Mkt Price 05/18 16:11 ET
High
49.090
Open
46.420
Turnover
44.24M
Low
45.600
Pre Close
48.330
Volume
942.31K
Market Cap
3.56B
P/E(TTM)
Loss
52wk High
202.730
Shares
75.85M
P/E(Static)
Loss
52wk Low
38.850
Float Cap
3.22B
Bid/Ask %
33.33%
Historical High
202.730
Shs Float
68.68M
Volume Ratio
0.70
Historical Low
9.180
Dividend TTM
--
Div Yield TTM
350
P/B
3.73
Dividend LFY
--
Div Yield LFY
745.63%
Turnover Ratio
1.37%
Amplitude
7.22%
Avg Price
46.949
Lot Size
1
Float Cap
3.22B
Bid/Ask %
33.33%
Historical High
202.730
Shs Float
68.68M
Volume Ratio
0.70
Historical Low
9.180
Dividend TTM
--
P/B
3.73
Dividend LFY
--
Turnover Ratio
1.37%
Amplitude
7.22%
Avg Price
46.949
Lot Size
1
Price Forecast

No Data

News

Comment